Harvard Bioscience (HBIO, Financial), a company specializing in scientific instruments for life science research, recently saw its stock rise by 5.17%, reaching $2.44 per share with a trading volume of 62,970 shares. The stock's turnover rate was 0.14%, with a price volatility of 4.96%.
Financial reports reveal the company generated $23.10 million in revenue, though it reported a net loss of $2.93 million, translating to an earnings per share (EPS) of -$0.07 and a gross profit of $11.89 million. The stock has a price-to-earnings (P/E) ratio of -9.74. Despite the earnings loss, both of the two rating institutions covering the stock have provided a buy recommendation, reflecting strong institutional support.
Within the broader medical equipment sector, which saw an overall increase of 0.72%, HBIO's performance stands out. Other notable gainers in the sector include Pulse Biosciences, Inc., and Singular Genomics Systems, Inc. Stocks like Innovative Eyewear, Inc. and Bionano Genomics, Inc. experienced high activity levels and significant turnover rates.
Harvard Bioscience is involved in developing, manufacturing, and selling products that support drug development, basic research, discovery, and pre-clinical testing. Its primary business focus is scientific instruments that advance life science research. The company operates in North America, Europe, and China, selling directly and through distribution channels to a global customer base. Key product brands include Harvard Apparatus, DSI, Buxco, and others, with most revenues derived from the U.S. market.
